Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
Avtorji:ID Mesti, Tanja (Avtor)
ID Ebert Moltara, Maja (Avtor)
ID Boc, Marko (Avtor)
ID Reberšek, Martina (Avtor)
ID Ocvirk, Janja (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (534,06 KB)
MD5: 9E8FC7EE5F8AE0DF84FC237948A95CEA
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. Patients and methods. The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospectively reviewed. All patients received bevacizumab (10 mg/kg) and irinotecan (340 mg/m2 or 125 mg/m2) every two weeks. Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated. Results. Between August 2008 and November 2011, 19 patients with recurrent malignant gliomas (median age 44.7, male 73.7%, WHO performance status 0%2) were treated with bevacizumab/irinotecan regimen. Thirteen patients had glioblastoma, 5 anaplastic astrocytoma and 1 anaplastic oligoastrocytoma. With exception of one patient, all patients had initially a standard therapy with primary resection followed by postoperative chemoradiotherapy. Radiological response was confirmed after 3 months in 9 patients (1 complete response, 8 partial responses), seven patients had stable disease and three patients have progressed. The median PFS was 6.8 months (95% confidence interval [CI]: 5.3-8.3) with six-month PFS rate 52.6%. The median OS was 7.7 months (95% CI: 6.6-8.7), while six-month and twelve-month survival rates were 68.4% and 31.6%, respectively. There were 16 cases of hematopoietic toxicity grade (G) 1-2. Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3. No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed. Conclusions. In recurrent malignant gliomas combination of bevacizumab and irinotecan might be an active regimen with acceptable toxicity.
Ključne besede:recurrent malignant glioma, systemic therapy, bevacizumab
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.03.2015
Založnik:Association of Radiology and Oncology
Leto izida:2015
Št. strani:str. 80-85, VI
Številčenje:Vol. 49, no. 1
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18723 Novo okno
UDK:616.8-006
ISSN pri članku:1318-2099
DOI:10.2478/raon-2014-0021 Novo okno
COBISS.SI-ID:1813371 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:17.04.2024
Število ogledov:481
Število prenosov:176
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:maligni gliom, bevacizumab, irinotecan, sistemska terapija


Nazaj